IL-1β is required for efficient priming of CD4+ T cells and interferone-γ (IFN-γ) producing tumor antigen-specific CD8+ CTLs (57) and therefore for the generation of an anti-tumor immune response. The gene discussed is IFNG; the disease is neoplasm.